# Evaluation of safety and efficacy of an auxotrophic aroA mutant live attenuated vaccine against piscine Streptococcus agalactiae infection

**Authors:** Meng Nie, Changming Guo, Yuhao Dong, Ting Xu, Yaru Sun, Yongjie Liu

PMC · DOI: 10.1038/s41541-026-01393-0 · 2026-02-05

## TL;DR

Researchers developed a safe and effective vaccine against a fish disease using a mutant strain of bacteria that lacks a key gene for amino acid production.

## Contribution

This is the first study to investigate the role of the aroA gene in Streptococcus agalactiae pathogenicity and demonstrate its potential for vaccine development.

## Key findings

- The aroA mutant showed reduced intracellular survival in macrophages and did not regain function with amino acid supplementation.
- The mutant vaccine provided full protection against lethal infection in tilapia at a specific dose.
- The aroA mutant was safe in multiple animal models, showing reduced endothelial damage and neuroinflammation.

## Abstract

Streptococcus agalactiae is a major pathogen threatening global tilapia aquaculture, causing severe economic losses due to high mortality. The rise of antimicrobial resistance necessitates the development of effective vaccines for streptococcosis control. Here, we generated an auxotrophic mutant through the targeted deletion of the aroA gene, which encodes a key enzyme in aromatic amino acid biosynthesis. The aroA mutant (ΔaroA) exhibited reduced intracellular survival within macrophages, a phenotype that was not restored by supplementation with exogenous aromatic amino acids under our experimental conditions. These findings suggest that aroA contributes to intracellular survival through mechanisms extending beyond its role in aromatic amino acid biosynthesis. In zebrafish, Nile tilapia and mouse models, ΔaroA demonstrated stable attenuation, reduced endothelial cell damage, and mitigated blood-brain barrier disruption and neuroinflammation, confirming its safety. The ΔaroA strain provided dose-dependent protection against lethal S. agalactiae challenges in both tilapia and mice, with 100% protection in tilapia conferred at a dose of 106 CFU following intraperitoneal administration. This study represents the first investigation into the role of aroA in S. agalactiae pathogenicity, providing valuable insights into the mechanisms of micronutrient utilization during bacterial pathogenesis. Also, our findings strongly support auxotrophic mutation as a promising attenuation strategy for vaccine development against streptococcosis in aquatic species.

## Linked entities

- **Genes:** aroA (phosphoshikimate 1-carboxyvinyltransferase) [NCBI Gene 884747]
- **Species:** Tilapia (taxon 8126), Streptococcus agalactiae (taxon 1311), Danio rerio (taxon 7955), Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** neuroinflammation (MESH:D000090862), Streptococcus agalactiae infection (MESH:D011008)
- **Chemicals:** aromatic amino acid (MESH:D024322), DeltaaroA (-)
- **Species:** Danio rerio (leopard danio, species) [taxon 7955], Streptococcus agalactiae (species) [taxon 1311], Mus musculus (house mouse, species) [taxon 10090], Tilapia (genus) [taxon 8126], Oreochromis niloticus (Nile tilapia, species) [taxon 8128]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12982791/full.md

---
Source: https://tomesphere.com/paper/PMC12982791